GENEDIT
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.
GENEDIT
Industry:
Biotechnology Genetics Pharmaceutical Therapeutics
Founded:
2016-04-04
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.genedit.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
43.73 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
Denali Therapeutics
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Porton Advanced Solutions
Porton Advanced Solutions provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Angel Round - GenEdit
Korea Investment Partners
Korea Investment Partners investment in Series A - GenEdit
KTB Network
KTB Network investment in Series A - GenEdit
IMM Investment
IMM Investment investment in Series A - GenEdit
Company K Partners
Company K Partners investment in Series A - GenEdit
Time Folio Asset Management
Time Folio Asset Management investment in Series A - GenEdit
Bow Capital
Bow Capital investment in Series A - GenEdit
Dayli Partners
Dayli Partners investment in Series A - GenEdit
Sequoia Capital
Sequoia Capital investment in Series A - GenEdit
SK Holdings
SK Holdings investment in Series A - GenEdit
Official Site Inspections
http://www.genedit.com Semrush global rank: 7.8 M Semrush visits lastest month: 437
Unable to get host informations!!!
More informations about "GenEdit"
GenEdit - Crunchbase Company Profile & Funding
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxyâ„¢ platform solves current delivery …See details»
About - GenEdit
Nov 12, 2024 At GenEdit, we aim to overcome the existing limitations in genetic medicine so we can positively impact the lives of as many people as possible. Our Vision. Our co-founders Kunwoo Lee, Ph.D., Hyo Min Park, Ph.D., and …See details»
Careers - GenEdit
GenEdit fosters an exciting and dynamic environment where we value impactful data and creative solutions to accelerate our progression from a platform technology to a pipeline of therapeutic candidates. We are seeking talented …See details»
Genedit Company Profile 2024: Valuation, Funding
Genedit General Information Description. Developer of curative therapies designed to solve the current gene therapy delivery challenges by systematically screening its proprietary nanoparticle library. The company's tool makes …See details»
GenEdit, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Earlier this year, Genentech signed a $644m collaboration agreement with biotech GenEdit to use the latter’s non-viral delivery platform for gene editing therapies against …See details»
GenEdit: Contact Details, Revenue, Funding, Employees and …
GenEdit focuses on overcoming the delivery challenges of genetic medicines using its NanoGalaxy platform, which features a library of non-viral, non-lipid polymer nanoparticles. …See details»
GenEdit - Overview, News & Similar companies | ZoomInfo.com
Jan 24, 2024 GenEdit has announced that Aaron Mishel, Chief Financial Officer, has left the organization to join Escient Pharmaceuticals as Chief Financial Officer. Sep 23 2021. ... At …See details»
GenEdit - Org Chart, Teams, Culture & Jobs - The Org
View GenEdit's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Genedit Inc. Company Profile | South San Francisco, CA
Find company research, competitor information, contact details & financial data for Genedit Inc. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
GenEdit - Contacts, Employees, Board Members, Advisors & Alumni
Organization. GenEdit . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. ... GenEdit has 8 board …See details»
A Brief History of GenEdit – CBM - canvasbusinessmodel.com
[cbm_blg_rlnkng]In the ever-evolving field of genetic editing, GenEdit stands as a pioneering company at the forefront of innovation. Founded in 2015 by a team of brilliant scientists and …See details»
GenEdit - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Pre Seed Round - GenEdit . …See details»
Who Owns GenEdit – CBM - canvasbusinessmodel.com
Oct 2, 2024 [cbm_blg_rlnkng]GenEdit is a cutting-edge biotechnology company at the forefront of genetic editing, poised to revolutionize the field of medicine and agriculture. ... Genetic …See details»
GenEdit Expands Leadership Team to Advance Targeted Genetic …
Sep 22, 2021 SOUTH SAN FRANCISCO, Calif., September 22, 2021 – GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo …See details»
GenEditBio
GenEditBio are working with efficient, versatile and safe gene editing tools which have distinct gene editing and targeting capabilities. Using these tools, we can access a broad range of …See details»
GenEdit - Updates, News, Events, Signals & Triggers - Crunchbase
GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.See details»
GenEdit Announces Multiyear Collaboration and License …
Jan 23, 2024 SOUTH SAN FRANCISCO, Calif., January 23, 2024 – GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy ® platform for tissue-selective delivery, …See details»
GenEditBio - Crunchbase Company Profile & Funding
GenEditBio is a biotech company that specializes in providing curative gene editing based solutions for genetic diseases.See details»
News - GenEdit
Nov 13, 2024 Catch up with the latest news, press releases and announcements from the GenEdit team. GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its …See details»